Find a Trial

Trial Summary

Protocol No.516-003
Principal InvestigatorAdra, Nabil
PhasePhase II
Age GroupAdult
TitleA Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients with Advanced or Metastatic Urothelial Carcinoma
DescriptionThe study will evaluate the clinical activity of nivolumab in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:
  • 18 years or older
  • Diagnosis of urothelial carcinoma
For a full list of participation criteria, please visit
Applicable Disease SitesOther Urinary
Participating InstitutionsIndiana University (IU)
    Treatment TypeTreatment
    ContactPhone: (317) 278-5632